Johnson K A, Ford L G, Kramer B, Greenwald P
Division of Cancer Prevention and Control, National Cancer Institute, Bethesda, Maryland 29892.
Acta Oncol. 1994;33(1):5-11. doi: 10.3109/02841869409098367.
The National Cancer Institute's (NCI) chemoprevention plan employs a strategy of basic and epidemiologic studies, followed by a structured preclinical process to bring chemopreventive agents into clinical testing. The field of chemoprevention is progressing rapidly and has reached the point where a coordinated international approach for large-scale trials would be useful. At present, NCI is sponsoring nine large trials (over $1 million per year per trial); in addition, nine agents are in phase I or II clinical testing. A number of these agents should be ready soon for phase III testing. Resources required for large-scale trials compel greater attention to efficient trial design, concept development and review, priority setting, management, budgeting, and collaboration.
美国国立癌症研究所(NCI)的化学预防计划采用了基础研究和流行病学研究策略,随后是一个结构化的临床前过程,以将化学预防剂带入临床试验。化学预防领域正在迅速发展,已经达到了需要采取协调一致的国际方法进行大规模试验的阶段。目前,NCI正在资助九项大型试验(每项试验每年超过100万美元);此外,有九种药物正处于I期或II期临床试验阶段。其中一些药物应很快准备好进行III期试验。大规模试验所需的资源促使人们更加关注高效的试验设计、概念开发与审查、优先级设定、管理、预算编制以及合作。